IQWiG says added benefit of AstraZeneca's Onglyza not proven

The German Institute for Quality and Efficiency in Health Care (IQWiG) has reassessed whether AstraZeneca’s (LSE: AZN) diabetes drugs Onglyza (saxagliptin) and the combination drug Komboglyze (saxagliptin and metformin) have advantages or disadvantages in comparison with the appropriate comparator therapies for the patients. The Institute concluded that an added benefit is not proven for the single agent or for the fixed combination.

The Federal Joint Committee G-BA distinguished four research questions for the single agent and two research questions for the fixed combination and defined the appropriate comparator therapies, which consisted of sulfonylureas, metformin, human insulin, and combinations of these drugs.

One study for all research questions